This report describes two patients with involuntary movements requiring dental treatment, under propofol sedation. The treatment was impossible because of exaggeration of the movements. Eventually adequate operating conditions were achieved with intravenous midazolam sedation.
CASE 1
A 65-year-old male was referred for treatment of extensive caries. He suffered from dental phobia. Medical health was good except for spasmodic torticollis. Despite medication (benzhexol hydrochloride 5 mg t.d.s., lorazepam 2 mg nocte, oxazepam 30 mg t.d.s., amitriptyline 25 mg t.d.s.) movements were poorly controlled.
The patient's dental treatment required three visits. Initially sedation was attempted with propofol infusion (initial rate 60 ml/h, reducing to 20 ml/h). Sedation was achieved within five minutes but movements worsened. Propofol was terminated and, after recovery, sedation attempted with incremental IV midazolam (total 7 mg), producing sedation for 25 minutes.
At the second appointment midazolam sedation was attempted. Incremental doses totalling 20 mg achieved light sedation for only 10 to 15 minutes. Between the second and third appointments the patient was commenced on selegiline (a monoamine oxidase B inhibitor).
At the third appointment sedation lasting 30 minutes was eventually achieved with incremental midazolam (total 30 mg).
CASE 2
A 56-year-old woman was referred for dental treatment under sedation, as Parkinson's disease prevented co-operation. Medical history showed a meningioma (surgically removed 1982), osteomyelitis (1986) resulted in removal of the skull plate, and Parkinson's disease. Her movements were poorly controlled despite apomorphine 2 mg 9 x daily, carbidopa 12.5 mg with levodopa 50 mg two hourly, diazepam 5 mg t.d.s., dihydrocodeine tartrate 60 mg t.d.s., selegiline 5 mg daily, temazepam 30 mg nocte, dihydrocodeine 10 mg and paracetamol 500 mg up to 8 x daily, and domperidone 10 mg up to 5x daily.
Dental treatment required four appointments. Initially sedation was attempted with propofol infusion (70 ml/hr, reducing to 10 ml/hr). After four minutes despite being sedated the movements increased. Propofol was discontinued and, after recovery, sedation continued with incremental midazolam (total 8 mg), allowing treatment.
During subsequent appointments, sedation lasting 35 minutes was achieved with incremental midazolam (average 13 mg) .
DISCUSSION
Propofol was used for sedation in these two cases as both patients were taking benzodiazepines. This may cause tolerance to intravenous midazolam as a consequence of the oral administration of other benzodiazepines 1 . The doses reported to be required to produce sedation in such patients are extremely large. The tolerance is mediated by an alteration in the response of the receptor site associated with the gamma amino butyric acid receptor complex, rather than increased elimination as a result of enzyme induction 2 . As a consequence there must be concern about the administration of such large doses of sedative agent. The receptor site tolerance does not appear to affect the actions of the benzodiazepines that are mediated via glycine receptors.
Many studies have compared intravenous propofol to midazolam [3] [4] [5] [6] . All have found propofol to have advantages, namely rapid recovery, easily altered sedation depth, and few side-effects [4] [5] [6] [7] . Propofol's effects on movement and convulsive disorders are unclear 8 . There are reports of involuntary movements on induction of and seizure-like activity after propofol anaesthesia (from short periods of opisthotonos during recovery to grand mal epileptic type convulsions-immediate or delayed) 9 . Propofol can control status epilepticus 10 . This paradox is interesting, as many patients suffering postoperative convulsions were epileptic 11 . Epilepsy is a contraindication to the administration of propofol 12 . Two cases have been described where propofol used to induce anaesthesia prior to stereotactic thalamotomy 13 abolished tremors for eight hours, making surgery impossible.
A search of the literature found no report of exacerbated involuntary movements, i.e. cases in which the patient was already suffering from a condition that caused involuntary movements, and where those movements increased in severity and/or rate as a result of the administration of propofol.
The only reasonable explanation for the aggravation pre-existing condition is that propofol exacerbated the involuntary movements.
We have used propofol sedation for patients receiving all types of dental treatment (routine conservation to osseointegrated implants) including benzodiazepine-tolerant patients 1 . Induction of sedation is smooth, depth is easily altered and recovery rapid.
The cases reported are quite different from others treated with propofol and such problems have not, to our knowledge, been previously described.
The possibility of a polypharmaceutical approach was considered at the third appointment for the first patient. He had started to take selegiline (an MAOI) between the second and third appointments. A polypharmaceutical approach to sedation is not popular in the U.K., and criticisms stress the dangers of mixing cocktails of drugs, particularly in patients with complicated drug histories. The British National Formulary warns of the problems of the concomitant administration of opioids and monoamine oxidase inhibitors: "CNS excitation or depression (hypertension or hypotension) if pethidine and possibly other opioid analgesics given to patients receiving MAOIs." This may be seen as contraindicating the use of opioids in such patients 14 . Such reactions have proved fatal with the traditional MAOIs, and although selegiline varies from the traditional action of such drugs by being a type B inhibitor, the use of pethidine would be contraindicated for two weeks following cessation of selegiline therapy. A search of the anaesthetic literature has not found any evidence to contraindicate the use of either morphine or fentanyl with MAOIs 15, 16 . It should be noted that the MAOIs will potentiate the generalized CNS depression produced by opioids, and thus a reduction in dose and careful clinical and electromechanical monitoring of such patients is required. A simpler approach, using a single sedative agent would be the treatment of choice, provided that a suitable technique could be found.
CONCLUSION
Individuals with a history of involuntary movement disorders may be more susceptible to increased movements during sedation with propofol.
